# SS&C Technologies Holdings Inc: financial statements, quarterly SSNC · Nasdaq · CIK 1402436 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ssnc.md) · [Financials](/companies/ssnc/financials.md) · [Filings](/companies/ssnc/filings.md) · [Insiders](/companies/ssnc/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ssnc/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,366](/filings/0000950170-24-118979.md) | [1,412 d](/filings/0001193125-26-076745.md) | [1,435](/filings/0000950170-25-061161.md) | [1,452](/filings/0000950170-25-100229.md) | [1,466](/filings/0001193125-25-258517.md) | [1,530 d](/filings/0001193125-26-076745.md) | [1,514](/filings/0001193125-26-197201.md) | [1,537](/filings/0001193125-26-326105.md) | [1,568](/filings/0001193125-25-258517.md) | [1,654 d](/filings/0001193125-26-076745.md) | [1,647](/filings/0001193125-26-197201.md) | [1,696](/filings/0001193125-26-326105.md) | | Cost of revenue | $m | [712](/filings/0000950170-24-118979.md) | [692 d](/filings/0001193125-26-076745.md) | [728](/filings/0000950170-25-061161.md) | [753](/filings/0000950170-25-100229.md) | [762](/filings/0001193125-25-258517.md) | [776 d](/filings/0001193125-26-076745.md) | [767](/filings/0001193125-26-197201.md) | [800](/filings/0001193125-26-326105.md) | [820](/filings/0001193125-25-258517.md) | [864 d](/filings/0001193125-26-076745.md) | [845](/filings/0001193125-26-197201.md) | [877](/filings/0001193125-26-326105.md) | | Gross profit | $m | [654](/filings/0000950170-24-118979.md) | [719 d](/filings/0001193125-26-076745.md) | [707](/filings/0000950170-25-061161.md) | [698](/filings/0000950170-25-100229.md) | [704](/filings/0001193125-25-258517.md) | [754 d](/filings/0001193125-26-076745.md) | [747](/filings/0001193125-26-197201.md) | [737](/filings/0001193125-26-326105.md) | [748](/filings/0001193125-25-258517.md) | [790 d](/filings/0001193125-26-076745.md) | [802](/filings/0001193125-26-197201.md) | [818](/filings/0001193125-26-326105.md) | | Research and development | $m | [118](/filings/0000950170-24-118979.md) | [118 d](/filings/0001193125-26-076745.md) | [121](/filings/0000950170-25-061161.md) | [129](/filings/0000950170-25-100229.md) | [131](/filings/0001193125-25-258517.md) | [137 d](/filings/0001193125-26-076745.md) | [129](/filings/0001193125-26-197201.md) | [128](/filings/0001193125-26-326105.md) | [119](/filings/0001193125-25-258517.md) | [132 d](/filings/0001193125-26-076745.md) | [135](/filings/0001193125-26-197201.md) | [132](/filings/0001193125-26-326105.md) | | Operating income | $m | [306](/filings/0000950170-24-118979.md) | [334 d](/filings/0001193125-26-076745.md) | [333](/filings/0000950170-25-061161.md) | [328](/filings/0000950170-25-100229.md) | [325](/filings/0001193125-25-258517.md) | [358 d](/filings/0001193125-26-076745.md) | [358](/filings/0001193125-26-197201.md) | [345](/filings/0001193125-26-326105.md) | [366](/filings/0001193125-25-258517.md) | [369 d](/filings/0001193125-26-076745.md) | [398](/filings/0001193125-26-197201.md) | [417](/filings/0001193125-26-326105.md) | | Interest expense | $m | [121](/filings/0000950170-24-118979.md) | [126 d](/filings/0001193125-26-076745.md) | [116](/filings/0000950170-25-061161.md) | [113](/filings/0000950170-25-100229.md) | [110](/filings/0001193125-25-258517.md) | [124 d](/filings/0001193125-26-076745.md) | [105](/filings/0001193125-26-197201.md) | [106](/filings/0001193125-26-326105.md) | [104](/filings/0001193125-25-258517.md) | [120 d](/filings/0001193125-26-076745.md) | [105](/filings/0001193125-26-197201.md) | [107](/filings/0001193125-26-326105.md) | | Income tax | $m | [51.2](/filings/0000950170-24-118979.md) | [81.8 d](/filings/0001193125-26-076745.md) | [66.7](/filings/0000950170-25-061161.md) | [13.8](/filings/0000950170-25-100229.md) | [60.0](/filings/0001193125-25-258517.md) | [(8.5) d](/filings/0001193125-26-076745.md) | [48.1](/filings/0001193125-26-197201.md) | [58.4](/filings/0001193125-26-326105.md) | [43.5](/filings/0001193125-25-258517.md) | [26.1 d](/filings/0001193125-26-076745.md) | [76.8](/filings/0001193125-26-197201.md) | [78.9](/filings/0001193125-26-326105.md) | | Net income | $m | [156](/filings/0000950170-24-118979.md) | [194 d](/filings/0001193125-26-076745.md) | [158](/filings/0000950170-25-061161.md) | [190](/filings/0000950170-25-100229.md) | [164](/filings/0001193125-25-258517.md) | [248 d](/filings/0001193125-26-076745.md) | [213](/filings/0001193125-26-197201.md) | [181](/filings/0001193125-26-326105.md) | [210](/filings/0001193125-25-258517.md) | [193 d](/filings/0001193125-26-076745.md) | [226](/filings/0001193125-26-197201.md) | [235](/filings/0001193125-26-326105.md) | | Diluted EPS | $ per share | [0.61](/filings/0000950170-24-118979.md) | not reported | [0.62](/filings/0000950170-25-061161.md) | [0.75](/filings/0000950170-25-100229.md) | [0.65](/filings/0001193125-25-258517.md) | not reported | [0.84](/filings/0001193125-26-197201.md) | [0.72](/filings/0001193125-26-326105.md) | [0.83](/filings/0001193125-25-258517.md) | not reported | [0.91](/filings/0001193125-26-197201.md) | [0.97](/filings/0001193125-26-326105.md) | | Basic EPS | $ per share | [0.63](/filings/0000950170-24-118979.md) | not reported | [0.64](/filings/0000950170-25-061161.md) | [0.77](/filings/0000950170-25-100229.md) | [0.67](/filings/0001193125-25-258517.md) | not reported | [0.87](/filings/0001193125-26-197201.md) | [0.74](/filings/0001193125-26-326105.md) | [0.86](/filings/0001193125-25-258517.md) | not reported | [0.94](/filings/0001193125-26-197201.md) | [0.99](/filings/0001193125-26-326105.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.4](/filings/0000950170-24-118979.md) | [0.4](/filings/0001193125-26-076745.md) | [0.4](/filings/0000950170-25-061161.md) | [0.5](/filings/0000950170-25-100229.md) | [0.7](/filings/0001193125-25-258517.md) | [0.6](/filings/0001193125-26-076745.md) | [0.5](/filings/0001193125-26-197201.md) | [0.5](/filings/0001193125-26-326105.md) | [0.4](/filings/0001193125-25-258517.md) | [0.5](/filings/0001193125-26-326105.md) | [0.4](/filings/0001193125-26-197201.md) | [0.4](/filings/0001193125-26-326105.md) | | Current assets | $bn | [2.3](/filings/0000950170-23-057447.md) | [4.1](/filings/0000950170-25-031295.md) | [3.5](/filings/0000950170-24-051251.md) | [3.1](/filings/0000950170-24-088968.md) | [3.9](/filings/0000950170-24-118979.md) | [4.9](/filings/0001193125-26-076745.md) | [6.2](/filings/0000950170-25-061161.md) | [4.7](/filings/0000950170-25-100229.md) | [5.3](/filings/0001193125-25-258517.md) | [5.5](/filings/0001193125-26-326105.md) | [5.3](/filings/0001193125-26-197201.md) | [5.7](/filings/0001193125-26-326105.md) | | Total assets | $bn | [16.2](/filings/0000950170-23-057447.md) | [18.1](/filings/0000950170-25-031295.md) | [17.4](/filings/0000950170-24-051251.md) | [16.9](/filings/0000950170-24-088968.md) | [18.4](/filings/0000950170-24-118979.md) | [19.0](/filings/0001193125-26-076745.md) | [20.4](/filings/0000950170-25-061161.md) | [19.0](/filings/0000950170-25-100229.md) | [19.5](/filings/0001193125-25-258517.md) | [20.7](/filings/0001193125-26-326105.md) | [20.3](/filings/0001193125-26-197201.md) | [20.6](/filings/0001193125-26-326105.md) | | Current liabilities | $bn | [2.0](/filings/0000950170-23-057447.md) | [3.8](/filings/0000950170-25-031295.md) | [3.1](/filings/0000950170-24-051251.md) | [2.7](/filings/0000950170-24-088968.md) | [3.2](/filings/0000950170-24-118979.md) | [4.4](/filings/0001193125-26-076745.md) | [5.6](/filings/0000950170-25-061161.md) | [4.1](/filings/0000950170-25-100229.md) | [4.8](/filings/0001193125-25-258517.md) | [5.1](/filings/0001193125-26-326105.md) | [4.9](/filings/0001193125-26-197201.md) | [5.4](/filings/0001193125-26-326105.md) | | Total liabilities | $bn | [10.0](/filings/0000950170-23-057447.md) | [11.7](/filings/0000950170-25-031295.md) | [10.9](/filings/0000950170-24-051251.md) | [10.4](/filings/0000950170-24-088968.md) | [11.6](/filings/0000950170-24-118979.md) | [12.4](/filings/0001193125-26-076745.md) | [13.5](/filings/0000950170-25-061161.md) | [12.0](/filings/0000950170-25-100229.md) | [12.5](/filings/0001193125-25-258517.md) | [13.8](/filings/0001193125-26-326105.md) | [13.4](/filings/0001193125-26-197201.md) | [13.9](/filings/0001193125-26-326105.md) | | Long-term debt | $bn | [6.7](/filings/0000950170-23-057447.md) | [6.7](/filings/0000950170-25-031295.md) | [6.6](/filings/0000950170-24-051251.md) | [6.6](/filings/0000950170-24-088968.md) | [7.2](/filings/0000950170-24-118979.md) | [7.0](/filings/0001193125-26-076745.md) | [6.8](/filings/0000950170-25-061161.md) | [6.8](/filings/0000950170-25-100229.md) | [6.6](/filings/0001193125-25-258517.md) | [7.4](/filings/0001193125-26-326105.md) | [7.3](/filings/0001193125-26-197201.md) | [7.3](/filings/0001193125-26-326105.md) | | Current portion of debt | $bn | [0.1](/filings/0000950170-23-057447.md) | [0.1](/filings/0000950170-25-031295.md) | [0.1](/filings/0000950170-24-051251.md) | [0.0](/filings/0000950170-24-088968.md) | [0.0](/filings/0000950170-24-118979.md) | [0.0](/filings/0001193125-26-076745.md) | [0.0](/filings/0000950170-25-061161.md) | [0.0](/filings/0000950170-25-100229.md) | [0.0](/filings/0001193125-25-258517.md) | [0.0](/filings/0001193125-26-326105.md) | [0.1](/filings/0001193125-26-197201.md) | [0.3](/filings/0001193125-26-326105.md) | | Shareholders' equity | $bn | [6.1](/filings/0000950170-23-057447.md) | [6.3](/filings/0000950170-25-031295.md) | [6.4](/filings/0000950170-24-051251.md) | [6.4](/filings/0000950170-24-088968.md) | [6.8](/filings/0000950170-24-118979.md) | [6.5](/filings/0001193125-26-076745.md) | [6.8](/filings/0000950170-25-061161.md) | [6.9](/filings/0000950170-25-100229.md) | [6.9](/filings/0001193125-25-258517.md) | [6.9](/filings/0001193125-26-326105.md) | [6.8](/filings/0001193125-26-197201.md) | [6.6](/filings/0001193125-26-326105.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [243 d](/filings/0000950170-24-118979.md) | [388 d](/filings/0001193125-26-076745.md) | [181](/filings/0000950170-25-061161.md) | [385 d](/filings/0000950170-25-100229.md) | [337 d](/filings/0001193125-25-258517.md) | [487 d](/filings/0001193125-26-076745.md) | [272](/filings/0001193125-26-197201.md) | [373 d](/filings/0001193125-26-326105.md) | [456 d](/filings/0001193125-25-258517.md) | [644 d](/filings/0001193125-26-076745.md) | [300](/filings/0001193125-26-197201.md) | [417 d](/filings/0001193125-26-326105.md) | | Capital expenditure | $m | [16.5 d](/filings/0000950170-24-118979.md) | [15.9 d](/filings/0001193125-26-076745.md) | [5.8](/filings/0000950170-25-061161.md) | [10.0 d](/filings/0000950170-25-100229.md) | [25.9 d](/filings/0001193125-25-258517.md) | [19.7 d](/filings/0001193125-26-076745.md) | [12.7](/filings/0001193125-26-197201.md) | [22.9 d](/filings/0001193125-26-326105.md) | [34.7 d](/filings/0001193125-25-258517.md) | [10.5 d](/filings/0001193125-26-076745.md) | [6.0](/filings/0001193125-26-197201.md) | [13.3 d](/filings/0001193125-26-326105.md) | | Dividends paid | $m | [161](/filings/0000950170-24-118979.md) | [60.0 d](/filings/0001193125-26-076745.md) | [59.7](/filings/0000950170-25-061161.md) | [120](/filings/0000950170-25-100229.md) | [183](/filings/0000950170-24-118979.md) | [62.3 d](/filings/0001193125-26-076745.md) | [61.6](/filings/0001193125-26-197201.md) | [123](/filings/0000950170-25-100229.md) | [65.8 d](/filings/0001193125-25-258517.md) | [65.5 d](/filings/0001193125-26-076745.md) | [65.3](/filings/0001193125-26-197201.md) | [64.0 d](/filings/0001193125-26-326105.md) | | Share repurchases | $m | [96.9 d](/filings/0000950170-24-118979.md) | [131 d](/filings/0001193125-26-076745.md) | [52.9](/filings/0000950170-25-061161.md) | [227 d](/filings/0000950170-25-100229.md) | [89.4 d](/filings/0001193125-25-258517.md) | [368 d](/filings/0001193125-26-076745.md) | [207](/filings/0001193125-26-197201.md) | [270 d](/filings/0001193125-26-326105.md) | [240 d](/filings/0001193125-25-258517.md) | [319 d](/filings/0001193125-26-076745.md) | [168](/filings/0001193125-26-197201.md) | [438 d](/filings/0001193125-26-326105.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [261](/filings/0000950170-23-057447.md) | [257](/filings/0000950170-24-051251.md) | [255](/filings/0000950170-24-088968.md) | [254](/filings/0000950170-24-118979.md) | [253](/filings/0000950170-25-061161.md) | [252](/filings/0000950170-25-100229.md) | [254](/filings/0001193125-25-258517.md) | [255](/filings/0001193125-26-197201.md) | [252](/filings/0001193125-26-326105.md) | [253](/filings/0001193125-25-258517.md) | [248](/filings/0001193125-26-197201.md) | [242](/filings/0001193125-26-326105.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 234,654,996 at 2026-07-23, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326105.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.